학술논문
Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells
Document Type
article
Author
Clara Gómez-Aleza; Bastien Nguyen; Guillermo Yoldi; Marina Ciscar; Alexandra Barranco; Enrique Hernández-Jiménez; Marion Maetens; Roberto Salgado; Maria Zafeiroglou; Pasquale Pellegrini; David Venet; Soizic Garaud; Eva M. Trinidad; Sandra Benítez; Peter Vuylsteke; Laura Polastro; Hans Wildiers; Philippe Simon; Geoffrey Lindeman; Denis Larsimont; Gert Van den Eynden; Chloé Velghe; Françoise Rothé; Karen Willard-Gallo; Stefan Michiels; Purificación Muñoz; Thierry Walzer; Lourdes Planelles; Josef Penninger; Hatem A. Azim; Sherene Loi; Martine Piccart; Christos Sotiriou; Eva González-Suárez
Source
Nature Communications, Vol 11, Iss 1, Pp 1-18 (2020)
Subject
Language
English
ISSN
2041-1723
Abstract
Receptor activator of nuclear factor-κB (RANK)/RANK-ligand (RANKL) signaling regulates the tumor-immune crosstalk. Here the authors show that systemic RANKL inhibition promotes CD8 + T cell infiltration in patients with early breast cancer and that loss of RANK signaling in tumor cells drives a T cell-dependent anti-tumor response in preclinical models.